HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of toxoplasma gondii induces immune response and protection against infection in mice.

Abstract
We have generated recombinant adenoviruses encoding three genetically modified surface antigens (SAGs) of the parasite Toxoplasma gondii, that is, AdSAG1, AdSAG2, and AdSAG3. Modifications included the removal of their glycosylphosphatidylinositol (GPI) anchoring motifs and, in some cases, the exchange of the native signal peptide for influenza virus hemagglutinin signal sequence. Adenovirus immunization of BALB/c mice elicited potent antibody responses against each protein, displaying a significant bias toward a helper T cell type 1 (Th1) profile in animals vaccinated with AdSAG1. Furthermore, the presence of parasite-specific IFN-gamma-producing T cells was analyzed by proliferation assays and enzyme-linked immunospot assays in the same animals. Splenocytes from immunized mice secreted IFN-gamma after in vitro stimulation with tachyzoite lysate antigen or with a fraction enriched for membrane-purified GPI-anchored proteins (F3) from the T. gondii tachyzoite surface. Epitopes recognized by CD8+ T cells were identified in SAG1 and SAG3, but not SAG2, sequences, although this protein also induced a specific response. We also tested the capacity of the immune responses detected to protect mice against a challenge with live T. gondii parasites. Although no protection was observed against tachyzoites of the highly virulent RH strain, a significant reduction in cyst loads in the brain was observed in animals challenged with the P-Br strain. Thus, up to 80% of the cysts were eliminated from animals vaccinated with a mixture of the three recombinant viruses. Because adenoviruses seemed capable of inducing Th1-biased protective immune responses against T. gondii antigens, other parasite antigens should be tested alone or in combination with those described here to further develop a protective vaccine against toxoplasmosis.
AuthorsBráulia C Caetano, Oscar Bruña-Romero, Blima Fux, Erica A Mendes, Marcus L O Penido, Ricardo T Gazzinelli
JournalHuman gene therapy (Hum Gene Ther) Vol. 17 Issue 4 Pg. 415-26 (Apr 2006) ISSN: 1043-0342 [Print] United States
PMID16610929 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, Protozoan
  • Membrane Glycoproteins
  • Protozoan Proteins
  • Protozoan Vaccines
  • SAG1 antigen, Toxoplasma
  • SAG3 protein, Toxoplasma gondii
  • Vaccines, Synthetic
  • surface antigen P22, Toxoplasma
Topics
  • Adenoviridae
  • Animals
  • Antigens, Protozoan (genetics, immunology)
  • Female
  • Gene Deletion
  • Immunity, Active
  • Immunity, Cellular
  • Membrane Glycoproteins (genetics, immunology)
  • Mice
  • Mice, Inbred BALB C
  • Protozoan Proteins (genetics, immunology)
  • Protozoan Vaccines (genetics, immunology)
  • Recombination, Genetic
  • Toxoplasma (immunology)
  • Toxoplasmosis, Animal (immunology, prevention & control)
  • Vaccines, Synthetic (genetics, immunology)
  • Virus Replication (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: